<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Anakinra improves the central <z:mp ids='MP_0008912'>nervous</z:mp> system manifestations of <z:hpo ids='HP_0003623'>neonatal-onset</z:hpo> multisystem <z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory disease</z:e>, which is mediated by IL-1beta oversecretion </plain></SENT>
<SENT sid="1" pm="."><plain>The cerebrospinal fluid (CSF) penetration of the IL-1 receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> anakinra was studied in rhesus monkeys after intravenous doses of 3 and 10 mg/kg </plain></SENT>
<SENT sid="2" pm="."><plain>Drug exposure (area under concentration-time curve) in CSF was 0.28% of that in serum </plain></SENT>
<SENT sid="3" pm="."><plain>The average CSF concentration at 3 mg/kg was 1.8 ng/mL, which is 30-fold higher than endogenous CSF levels of IL-1Ra </plain></SENT>
<SENT sid="4" pm="."><plain>The CSF penetration was not dose-dependent, indicating that the CSF penetration was not saturated in the 3 to 10 mg/kg dose range </plain></SENT>
</text></document>